How The Prostate Cancer Market Will Look Over Next Decade
As generic competition to J&J's Zytiga starts to line up ahead of possible launches in October, Datamonitor Healthcare has been weighing up the prostate cancer therapy space and seeing where the future competition will come from for Pfizer and Astellas' market leader Xtandi.
You may also be interested in...
ASCO GU: Darolutamide is important for the company's oncology portfolio, but does it have enough to compete against J&J's Erleada and Pfizer/Astellas' Xtandi?
While multiple new approaches and drugs are being developed for different stages of prostate cancer globally, many remain unavailable across Asia Pacific markets, despite a rising overall incidence of the disease. Two specialists recently shared with Scrip their views on treatment issues and optimum approaches in this fast-changing environment, and how they see the broader role of existing and new therapies developing given recent clinical results and practice.
Recent launches Tremfya and Erleada are viewed as catalysts for continuing growth, along with ambitious plans to add indications for Imbruvica, Darzalex and Stelara.